Race Oncology Limited announced Executive Director and Chief Scientific Officer, Dr. Daniel Tillett has advised his decision to step down from his roles. Dr. Tillett will provide ongoing support through June 2023 to ensure a smooth transition of his CSO responsibilities to the Race team, with oversight from Professor Tim Hammond, who will assume the role of Interim CSO. Dr. Tillett joined Race initially as a major shareholder in 2019 growth and transformation.

Dr. Tillett joined Race initially as a major shareholder in 2019 and subsequently joined the Board, later stepping into the vacant position of Chief Scientific Officer, while contributing broadly to Race's strategic evolution as an Executive Director. His tenure has been underscored by several major achievements, including the discovery of the cardioprotective properties of Zantrene®, which has opened substantial new market opportunities. Dr. Tillett is succeeded as CSO by Prof Tim Hammond of Advonate Clinical, who commenced on 23 March 2023 on an interim basis, pending the appointment of a full time CSO.

Prof Hammond will work closely with Race's executive and clinical teams who have been intimately involved in all aspects of the design and implementation of Race's clinical programs. Adnovate Clinical has been a key partner of the Company over the past 6 months. Interim CSO, Prof Hammond has 35 years of experience in pharmaceutical drug discovery and development and was a former Vice President of Safety Assessment in the UK for AstraZeneca. During his time at AstraZeneca, he was responsible for the non-clinical safety development of the full oncology portfolio including registration of Irressa and Olaparib and has extensive experience in the development of small molecules, peptides, monoclonal antibodies and gene therapy projects in oncology.

Prof Hammond's already established collaboration with Race and passion for drug development will help to optimise the scientific agenda created by Dr. Tillett and the Race team.